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Abstract
According to numerous studies, a high prevalence of iron deficiency (ID) with anaemic syndrome and its association with mor-
tality during chronic heart failure (CHF) have been revealed. Ferrocorrection of anaemia during CHF is important both to improve the 
clinical condition and to optimize the long-term prognosis of patients. However, the pathogenetic justification is the use of agents that 
have antihypoxic, antioxidant and membrane-stabilizing effects, except iron preparations, and at the same time exert a regulatory effect 
on the metabolism of physiologically active compounds and improve the functional condition of patients. 
The aim. The aim of this study was to identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy 
with L-carnitine on exercise tolerance (ET) of patients with CHF with reduced ejection fraction of left ventricle (LVEF) with concomi-
tant iron deficiency anemia (IDA) was determined and compared.
Materials and methods. The study includes 62 patients with CHF with reduced LVEF FC II-III according to NYHA with IDА. 
Patients with hypertensive and ischemic etiology of HF took part in the study. Among them, 45 (72.6 %) were men and 17 (27.4 %) were 
women aged 70.0±0.9 years. Two study groups were formed: in addition to the standard therapy, the patients in the 1st group (n=32) were 
prescribed oral ferrous sulfate in a dose of 320 mg, equivalent to 100 mg of bivalent iron and 60 mg of ascorbic acid 2 tablets per day for 
6 months; the patients in the 2nd group (n=30) received the standard therapy of CHF and not only iron, but also L-carnitine.
Results and discussion. The use of two variants of ferrocorrection as an application to the standard treatment of CHF among the 
total number of studied patients with IDA indicates the sufficient effect both to eliminate the signs of anemia and to eliminate ID. The 
analysis of the dynamics of the passed test distance with a 6-minute walk in 32 patients with IDA on the background of standard treat-
ment and additional ferrotherapy after 6 months showed an increase of the actual distance by 8.9 % (from 249.4 to 272.3 m, p<0.0001). 
The analysis of changes in the value of travelled distance among patients with IDA who received combined 6-month ferrotherapy with 
L-carnitine also revealed a significant positive trend. In addition, the value obtained was significantly higher compared to the results of 
patients with only additional ferrotherapy, an increase of 19.4 % (from 259.5 to 304.5 m, p<0.0001). 
Conclusions. The use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase in ET, which is reflected 
in a significantly longer test distance with a 6-minute walk and greater frequency of decrease of FC of HF among patients, compared 
with using only iron sulfate ferrocorrection.
Keywords: chronic heart failure, iron deficiency anemia, indices of iron metabolism.
DOI: 10.21303/2504-5679.2019.001085
1. Introduction
Today, the question of the importance of iron deficiency (ID) as a new therapeutic goal 
for reducing symptoms, quality of life (QOL) and prognosis of patients with chronic heart failure 
(CHF) is rather acute [1, 2]. 
The prevalence of anemia as a manifest form of ID of patients with HF reaches about 30 % 
in outpatient and about 50 % in hospitalized patients [3]. According to the above numbers, it can 
be concluded that ID is a very common comorbidity of CHF, which is known to be independent of 
sex, race and left ventricular (LV) ejection fraction (EF) (LVEF) [3], but is related to age [4] and 
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increase in functional class (FC) of chronic heart failure according to NYHA classification – at FC 
III to 33 % and at FC IV to 80 % [5, 6].
Numerous studies aimed at identifying the causes and mechanisms of occurrence of ID with 
and without anemic syndrome during CHF, have found that proinflammatory activity and anemia of 
chronic disease (ACD) [7] are the most common causes of anemia of patients with CHF [1]. In other 
words, ID during CHF is more often functional. Whereas, manifest absolute ID –IDA among the total 
number of anemic patients with CHF is less common [1]. However, regardless of the variant of iron 
metabolism disorder that underlies the development of anemia, patients with ID present a significant 
problem for practical health care since the anemia syndrome during CHF is associated with an increase 
in mortality and the frequency of hospitalizations of patients [3, 8, 9]. In addition, ID independently of 
anemia contributes to the development of skeletal muscle dysfunction, which in turn causes a decrease 
in exercise tolerance (ET) of patients and serves as an independent factor in reducing the QL of patients 
[10, 11]. When anemia occurs, there are compensatory hemodynamic mechanisms that lead to the pro-
gression of HF and consequently further reduce ET and clinical condition of patients [5].
At the same time, it is known that effective correction of anemic syndrome of patients with 
CHF improves the condition and clinical prognosis [5]. According to modern approaches to cor-
rection of IDA of patients with CHF the most often are used peroral and parenteral ferrocorrection.
However, the modern pharmacological strategy for the treatment of IDA of patients with 
CHF must take into account, without fail, the nature of metabolic disorders that occur simultane-
ously with iron metabolism disorders. The pathogenetic justification is the use of agents that have 
antihypoxic, antioxidant and membrane-stabilizing effects, except iron preparations, and at the 
same time exert a regulatory effect on the metabolism of physiologically active compounds and 
improve the functional condition of patients.
The aim of this study was to identify and compare the effect of oral ferrotherapy and com-
bined use of ferrotherapy with L-carnitine on exercise tolerance of patients with chronic heart 
failure with reduced ejection fraction of left ventricle with concomitant iron deficiency anemia.
2. Materials and methods
The study includes 62 patients with CHF with reduced LVEF FC II-III according to NYHA 
with IDА. Patients with hypertensive and ischemic etiology of HF took part in the study. Among 
them, 45 (72.6 %) were men and 17 (27.4 %) were women aged 70.0±0.9 years. All patients were 
hospitalized in the therapeutic departments of the Vinnytsia Regional Clinical Hospital of War 
Veterans in the period from 2013 to 2017.
The study was conducted with the consent of patients in accordance with the basic bioeth-
ical standards of the World Health Association Declaration on Ethical Principles for Conducting 
Scientific and Medical Research as amended (2008), Universal Declaration of Bioethics and Hu-
man Rights (1997), Council of Europe Convention on Human Rights and Biomedicine (1997). Pa-
tients’ consent, together with other documents related to the study, were approved at the meeting of 
the Academic Council of National Pirogov Memorial Medical University, Vinnytsya (excerpt from 
protocol No. 4 of 26.04.2016)
During the selection phase, all patients underwent general clinical examination with a com-
pulsory laboratory assessment of hemoglobin (Hb), red blood cells (Rbc), color index (CI), hema-
tocrit, Rbc indices: MCV, MCH, MCHC and levels of serum iron (SI), ferritin, total iron-binding 
capacity of serum (TIBC) and transferrin saturation (TS).
For the diagnosis of IDА, the following criteria were used: 
1) a decrease Hgb level in men <130 g/l and in women <120 g/l; 
2) SI in women <11.5 µmol/l and in men <13.0 µmol/l; 
3) ferritin level <100 ng/ml. 
Anemia of mild degree was determined in the case of Hgb values – 110–119 g/l for women 
and 110–129 g/l for men, moderate – within 109-80 g/l and severe – <80 g/l, as for women and for 
men (WHO, 2011). Only patients with mild and moderate anemia were included in the study.
To determine the changes of effort tolerance (ET) in patients during treatment, the dynamics 
analysis of the covered six-minute walk test distance was conducted.
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According to the study design, all patients received standard therapy indicated by modern 
ESC recommendations, taking into account ischemic and hypertensive etiology of CHF and co-
morbid conditions, such as atrial fibrillation.
In order to avoid the possible impact of standard treatment on the results of ferrotherapy, 
standard drug regimens were prescribed. Drug dosages were selected individually, taking into 
account the patients’ clinical condition. 
Two study groups were formed: in addition to the standard therapy, the patients in the 1st 
group (n=32) were prescribed oral ferrous sulfate in a dose of 320 mg, equivalent to 100 mg of bi-
valent iron and 60 mg of ascorbic acid 2 tablets per day for 6 months; the patients in the 2nd group 
(n=30) received the standard therapy of CHF and not only iron, but also L-carnitine.
The groups of patients were compared by gender, age, main clinical characteristics and 
treatment (Table 1).
Table 1
Clinical characteristics of patients with CHF with reduced EF of LV depending on additional treatment
Characteristics 6-month ferrotherapy n=32
6-month ferrotherapy with L-carnitine 
n=30
Age, years (М±σ) 70.9±1,2 69.2±1.4
Sex, %:
Men 62.5 75
Women 37.5 25
Angina pectoris, % 46.9 53.3
Myocardial infarction, % 31.3 33.3
Diabetes, % 28.1 36.7
FC CHF, %
II FC 18.8 26.7
III FC 81.2 73.3
Hematological parameters, median  
(lower, upper quartile): 
Hb, g/l 106.5 (96.5; 116.5) 108 (97; 116)
Rbc, ×1012/l 4.25 (3.9; 4.48) 3.9 (3.87; 4.45)
СІ 0.77 (0.70; 0.84) 0.80 (0.7; .82)
Hсt, l/l 0.32 (0.32; 0.36) 0.32 (0.31; 0.35)
MCV, fl 80.5 (77.1; 81.9) 81.9 (79.5; 83.3)
MCH, pg 25.6 (23.2; 28) 26.4 (24.5; 27.2)
МСНС, g/l 318 (308.7; 327.9) 322.7 (312.5; 340.6)
SI, umol/l 7,9 (6,2; 10,3) 9,55 (6,4; 11,2)
Ferritin, μg/l 63 (41; 82.5) 43.5 (31; 76)
TS, % 11.1 (8; 13.3) 12.8 (8; 15.2)
TIBC, umol/l 77 (67.5; 87.7) 74.1 (68.2; 86.5)
Medication/Group of medications, %:
ACE inhibitors 66.1 53.3
ARBs 33.9 30
β-blockers 91.9 88.3
Spironolactone 95.2 98.3
Digoxin 11.3 8.3
Nitrates 37.1 20
Amlodipine 43.5 40
TD/TLD 43.5 43.3
Warfarin 11.3 11.7
ASA 88.7 88.3
Atorvastatin 100 100
Amiodarone 12.9 13.3
Note: ACE inhibitors – angiotensin converting enzyme inhibitors, ARBs – angiotensin II receptor blockers, β-blockers – beta-adren-
ergic blocking agents, ASA – acetylsalicylic acid, TD/TPD – thiazide and thiazide-like diuretics
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Statistical processing of the obtained results was performed using the software package 
Microsoft Office Excel and Statistica. Due to abnormal distribution of data, the obtained measure-
ments are presented as a median (lower, upper quartile). The statistical significance of the differ-
ence in the measured parameters among the groups was calculated according to Kruskal-Wallis 
ANOVA & Median test for all groups criterion, and the difference between the results of 6-month 
treatment and the output values was calculated according to Wilcoxon matched pairs test criterion. 
The difference in the frequency of signs (%) was calculated by the χ2 criterion. The difference was 
considered reliable at p<0.05. 
3. Results
The use of two variants of ferrocorrection as an application to the standard treatment of 
CHF among the total number of studied patients with IDA indicates the sufficient effect both to 
eliminate the signs of anemia and to eliminate ID. A comparative analysis of the clinical and he-
matological effectiveness of 6-month oral ferrotherapy with iron sulfate and the effectiveness of 
combined ferro- and metabolic therapy showed no difference since the intergroup distribution of 
patients with different hematological evolution in the two treatment groups did not differ (p=0.83) 
(Table 2). In both groups, the percentage of patients with eliminated IDA was predominant. 
Table 2
Distribution of patients with CHF with reduced LVEF depending on hematological evolution after 
treatment (in %)
Clinical-hematological characteristics 6-month ferrotherapy n=32
6-month ferrotherapy with L-carnitine 
n=30
IDA 9.4 10
ACD and IDA 3.1 0 
Without ID 68.8 76.7
Functional ID 3.1 3.3
Absolute ID 15.6 10
Note: The cross-group difference in % of different variants of hematological evolution between the two treatment groups which was 
calculated by χ2 criterion, is unreliable (р=0.83)
Comparison of the studied laboratory parameters of patients with IDA after 6 months with 
different options for additional treatment revealed no difference in the increase in hematological 
parameters, except for the levels of Hct, which were higher for patients who received additional 
L-carnitine. In addition, in patients receiving metabolic therapy, there was a tendency to a greater 
increase in Hgb and Rbc (Table 3).
Table 3
Comparison of hematological parameters of patients with CHF with reduced LVEF with IDA after treatment, 
median (lower, upper quartile)
Parameters
6-month ferrotherapy 
n=32
6-month ferrotherapy with L-carnitine 
n=30
Initial value 6th month Dynamics, % Initial value 6th month Dynamics, %
1 2 3 4 5 6 7
Hb, g/l 106.5 (96.5; 116.5)
138 
(131.5; 147)**
+28.6  
(+25.3; +34.5)
108 
(97; 116)
141 
(134; 147)**
+31.6 
(+24.8; +36.8)
Rbc, ×1012/l 4.25 (3.9; 4.48)
4.6 
(435; 4.9)**
+8.9 
(+3.9; +14.6)
3.9 
(3.87; 4.45)
4.6 
(4.3; 4.9)**
+11.5 
(+5.6; +15.6)
СІ
0.77 
(0.70; 0.84)
0.88 
(0.86; 0.94)**
+17.6 
(+8; +22)
0.80 
(0.7; .82)
0.91 
(0.89; 0.95)**
+15.9 
(+8.3; +22.2)
Hсt, l/l
0.32 
(0.32; 0.36)
0.37 
(0.35; 0.41)**
+12.5 
(+9.2; +21.5)
0.32 
(0.31; 0.35)
0.39 
(0.37; 0.4)**
+19.6 
(+14.1; +25)#
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Continuation of Table 3
1 2 3 4 5 6 7
MCV, fl 80.5 (77.1; 81.9)
83.8 
(77.2; 86.8)*
+6 
(–1.5; +10.7)
81.9
(79.5; 83.3)
85.8 
(80; 90)*
+6.7 
(+0.4; +10.8)
MCH, pg 25.6 (23.2; 28)
29.3 
(28.4; 31.1)**
+17.6 
(+8; +28)
26.4 
(24.5; 27.2)
30.3 
(29.5; 31.4)**
+15.9 
(+8.3; +22.2)
МСНС, g/l 318 (308.7; 327.9)
358 
(339.2; 384)**
+12.6 
(+7.5; +19.6)
322.7 
(312.5; 340.6)
351.9 
(343.6; 371)**
+9.4 
(+0.80; +14.8)
SI, umol/l 7.9 (6.2; 10.3)
15.3 
(12.9; 18)**
+82.6 
(+63.6; an 
increase of 2.1 
times)
9.55 
(6.4; 11.2)
16 
(13.7; 18.4)**
+87.2 
(+62.8; an 
increase of 2.1 
times)
Ferritin, μg/l 63 (41; 82.5)
133.5 
(99; 179)**
an increase 
of 2.3 times 
(+90.4; of 3.2 
times)
43.5 
(31; 76)
119 
(104; 158)**
an increase of 
2.5 times 
(of 2; of 3.2 
times)
TS, % 11.1 (8; 13.3)
23.7 
(17.7; 30)**
an increase of 
2.2 times (+77.8; 
of 2.8 times)
12.8 
(8; 15.2)
27 
(20.4; 32.3)**
an increase of 
2.2 times (+76.8; 
of 2.8 times)
TIBC, umol/l 77 (67.5; 87.7)
65.5 
(59; 74.5)**
–13.6 
(–17.7; –7.4)
74.1 
(68.2; 86.5)
64.1 
(57; 69)**
–17.8 
(–22.5; –7.47)
Note: * – p<0.01 when compared with initial values; ** – p<0.0001 when compared with initial values; # – p<0.05 when comparing 
values of different observation groups after treatment
The analysis of the dynamics of the passed test distance with a 6-minute walk in 32 patients 
with IDA on the background of standard treatment and additional ferrotherapy after 6 months 
showed an increase of the actual distance by 8.9 % (from 249.4 to 272.3 m, p<0.0001) (Fig. 1). The 
analysis of changes in the value of travelled distance among patients with IDA who received com-
bined 6-month ferrotherapy with L-carnitine also revealed a significant positive trend. In addition, 
the value obtained was significantly higher compared to the results of patients with only additional 
ferrotherapy, an increase of 19.4 % (from 259.5 to 304.5 m, p <0.0001). 
Fig. 1. The dynamics of the covered six-minute walk test distance in patients with CHF with 
reduced LVEF and IDA on the background of the treatment: pid-6 – reliability of differences 
between initial distance and post-treatment distance; pid, 1-2 – reliability of initial distance 
differences between two treatment groups; p6, 1-2 – reliability of distance differences after  
6 months of observations between two treatment groups; p
Δ, 1-2 – reliability of changes difference 
between two treatment groups
Analysis of the distribution of CHF FC by NYHA among all patients with IDA showed a 
significant positive dynamics and reduction of FC by 1 class during treatment compared to the 
initial distribution in 14 (22.6 %) patients (p<0.0001). 
Evaluation of changes in FC dynamics on the background of different treatment revealed 
a tendency (p<0.08) to increase the number of cases of reduction of FC CHF by NYHA in pa-
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tients treated with iron and L-carnitine, compared with patients treated only with ferrotherapy 
(26.7 % vs. 18.8 %, respectively). 
4. Discussion
Taking into account the disadvantages of oral ferrocorrection – slow absorption in the gas-
trointestinal tract and its decreased level in conditions of minimal possible inflammation in case of 
CHF and due to blood congestion, in order to improve patients’ physical functioning and general 
condition, oral ferrotherapy in patients with CHF and concomitant IDA was prolonged in our study. 
In our study, the obtained data show that hematological indices dynamics in patients who received 
6-month ferrotherapy as markers of ferrocorrection efficacy, demonstrated an increase in all pa-
rameters and corresponding normalization of iron metabolism indices and to eliminate the signs of 
anemia in most cases. Thus, it can be argued that ferrotherapy with iron sulfate at the stage of iron 
deficiency anemia in patients with heart failure with reduced left ventricular ejection fraction for 
a period of 6 months is effective. In addition, positive hematologic dynamics was accompanied by 
a major improvement in effort tolerance indices. Because ID, even in the absence of anemia, is a 
factor of a decrease of physical capacity and quality of life [12] and medicated correction of ID in 
case of CHF brings positive changes in patients’ condition.
However, long-term oral ferrotherapy can only be used in patients with absolute ID. IDА is 
caused by the multifactorial depletion of iron in the body and the main way of its correction is the 
use of oral or intravenous iron. Hepcidin function to block intestinal iron absorption and iron re-
lease from the mononuclear-phagocyte system, which occur due to activation of proinflammatory 
cytokines, have an impact on the development of ACD as a functional ID. Therefore, the use of oral 
iron supplements in this type of ID is not effective, and moreover, dangerous due to possible oc-
currence of hemosiderosis [1]. Therefore, for the effective treatment of patients with CHF and iron 
deficiency with anemic syndrome, it is necessary to differentiate the variant of iron metabolism by 
biochemical parameters.
L-carnitine is a vitamin-like and modified amino acid that plays an important role in sup-
porting the body’s metabolic activities. There is growing evidence that high concentrations of 
L-carnitine provide beneficial effects in various diseases such as coronary artery disease, con-
gestive heart failure, peripheral vascular diseases, type 2 diabetes, dyslipidemia, and hyperten-
sion [13–16]. However, as a treatment of heart failure, L-carnitine has not been recommended in 
patients with current or prior symptoms of heart failure with reduced ejection fraction and heart 
failure with preserved ejection fraction in the American guideline [17, 18]. The recommendation of 
nutritional supplements has not been proposed in the European guideline [19].
Our study demonstrated that despite the same hematological efficacy, oral ferrotherapy and 
ferrotherapy in combination with the use of L-carnitine in patients with CHF with reduced LVEF 
and concomitant IDA have a positive clinical efficacy in relation to the physical ability of patients. 
However, the use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase 
in ET, compared with using only iron sulfate ferrocorrection. 
Thus confirmed that L- carnitine represents a safe and effective adjuvant therapy which, by 
increasing high energy phosphate for systolic function, may have a synergistic effect with other 
drugs [12, 20]. L-carnitine treatment in CHF patients may improve clinical symptoms and the 
physical capacity, which is particularly relevant for anemic patients. Therefore, the proposed treat-
ment regimen may be recommended for use as additional treatment for patients with chronic heart 
failure with reduced left ventricular ejection fraction and concomitant iron deficiency anemia.
Limitations of the study. For patients with CH and iron deficiency, it is necessary to 
determine its type. It can be diagnosed only by determining the biochemical parameters of iron 
metabolism that is not routinely used. However, this is a way to help determine an effective 
treatment method.
Prospects for further research. Because the use of metabolic therapy with oral ferrother-
apy is accompanied by a greater increase in ET compared with using only iron sulfate ferrocorrec-
tion, there is a need to identify the effect of combined use of ferrotherapy with L-carnitine on others 
clinical and instrumental parameters of patients with CHF with reduced LVEF.
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5. Conclusions
The use of oral 6-month ferrotherapy and 6-month ferrotherapy in combination with L-car-
nitine in the treatment of CHF with reduced EF of LV with concomitant IDA eliminated anemia in 
87.5 % and 90 % of patients, and iron deficiency in 68.8 % and 76.7 %, respectively. Which in turn 
allows us to attest to the sufficient effect of the two options for additional treatment of CHF with 
concomitant IDA, both to eliminate the signs of anemia and to eliminate ID. 
Despite the same hematological efficacy, oral ferrotherapy and ferrotherapy in combination 
with the use of L-carnitine as adjunct options to the standard treatment of CHF with reduced LVEF 
with concomitant IDA have a positive but different clinical efficacy in relation to the physical abil-
ity of patients. 
The use of metabolic therapy with oral ferrotherapy is accompanied by a greater increase in 
ET, which is reflected in a significantly longer test distance with a 6-minute walk and greater frequen-
cy of decrease of FC of HF among patients, compared with using only iron sulfate ferrocorrection.
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Abstract
Multimodal analgesia for lumbar spine surgery is still a controversial problem, because of possible fusion problems, signifi-
cant neuropathic component of pain, and influence of anesthesia type. Aim of the study was to assess the efficacy of pain manage-
ment after lumbar spine surgery considering characteristics of pain, type of anesthesia and analgesic regimen.
Material and methods. 254 ASA I–II patients with degenerative lumbar spine disease were enrolled into prospective study. 
Patients were operated either under spinal anesthesia (SA) or total intravenous anesthesia (TIVA). In postoperative period patients 
got either standard pain management (SPM – paracetamol±morphine) or multimodal analgesia (MMA – paracetamol+parecoxib+ 
+pregabalin±morphine).
Results. We revealed neuropathic pain in 53.9 % of patients, who were elected for lumbar spine surgery. VAS pain score in 
patients with neuropathic pain was higher, than in patients with nociceptive pain. Total intravenous anesthesia was associated with 
greater opioid consumption during the first postoperative day. Multimodal analgesia based on paracetamol, parecoxib and pregabalin 
allowed to decrease requirements for opioids, postoperative nausea and dizziness. Pregabalin used for evening premedication had 
equipotential anxiolytic effect as phenazepam without postoperative cognitive disturbances.
Conclusions. Multimodal analgesia is opioid-sparing technique that allows to decrease complications. Spinal anesthesia is 
associated to a decreased opioid consumption in the 1st postoperative day.
Keywords: lumbar spine surgery, anesthesia, multimodal analgesia.
DOI:10.21303/2504-5679.2019.001068
© The Author(s) 2019
This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0).
Received date 30.10.2019
Accepted date 19.11.2019
Published date 30.11.2019
